

Run Date: 06/24/23
Run Time: 0029

Phone:

Medical Director:

PATIENT	SEX	AGE	DATE OF BIRTH	LOCATION	DATE PRINTED
Miller, John R	M	70	12/31/1952	SLCLAB	06/24/23
					@ 0029
MED REC # / ACCT #	ADMIT DATE	DISCH DATE	SUBMITTING DOCTOR		
SL30005675 / RQ0010049799	06/20/23		Joanie Salotti, NP		

Hematology

Date	06/20/2023		
Time	1225		
		Reference	Units
WBC	4.82(*a)	(4.0-10.4)	x10 ³ /
RBC	4.95(*a)	(3.90-5.90)	x10 ⁶ /
HGB	15.3(*a)	(12.4-17.4)	g/dL
HCT	45.0(*a)	(36.0-50.0)	%
MCV	90.9(*a)	(86.0-100.0)	fL
MCH	30.9(*a)	(27.5-33.5)	pg
MCHC	34.0(*a)	(31.8-35.8)	g/dL
RDW	13.2(*a)	(10.8-15.3)	%
Plt	230(*a)	(138-373)	x10 ³ /
MPV	8.9(*a)	(8.2-11.6)	fL
Im Gran% (Auto)	0.4(*a)	(0.0-0.6)	%
Neut % (Auto)	64.8(*a)	(41.1-75.5)	%
Lymph % (Auto)	23.0(*a)	(15.5-46.5)	%
Mono % (Auto)	10.4(*a)	(3.6-11.4)	%
EOS % (Auto)	1.2(*a)	(0.0-5.8)	%
Baso % (Auto)	0.2(*a)	(0.0-1.2)	%
Im Gran# (Auto)	0.02(A)	(0.00-0.31)	x10 ³ /

(A) See (B), (*a)

(B) The IG (immature granulocytes) is the total instrument count of combined metamyelocytes, myelocytes and promyelocytes

Neut # (Auto)	3.12(*a)	(1.30-7.60)	x10 ³ /
Lymph # (Auto)	1.11(*a)	(1.10-3.50)	x10 ³ /
Mono # (Auto)	0.50(*a)	(0.20-0.90)	x10 ³ /
EOS # (Auto)	0.06(*a)	(0.00-0.50)	x10 ³ /
Baso# (Auto)	0.01(*a)	(0.00-0.10)	x10 ³ /
nRBC Abs	0.0000(*a)	(0.0000-0.0)	x10 ³ /
NRBC%	0.0(*a)	(0.0-0.2)	%

NOTES: (*a) Salt Lake Regional Lab
Salt Lake Regional Medical Center Laboratory, 1050 E S Temple
Salt Lake City, UT 84102
Richard Iverson, DO

RQ0010049799 - Miller, John R (SL30005675) DEP(/) 70/M Joanie Salotti, NP

Run Date: 06/24/23
Run Time: 0029

Phone:

Medical Director:

PATIENT	SEX	AGE	DATE OF BIRTH	LOCATION	DATE PRINTED
Miller, John R	M	70	12/31/1952	SLCLAB	06/24/23
MED REC # / ACCT #	ADMIT DATE	DISCH DATE	SUBMITTING DOCTOR		
SL30005675 / RQ0010049799	06/20/23		Joanie Salotti, NP		

Coagulation

Date	06/20/2023		
Time	1225	Reference	Units
PT	10.6(*b)	(9.3-12.1)	Second
INR	1.0(C)	(0.9-1.2)	

(C) See (D), (*b)

(D) Reference Interval is for non-anticoagulated patients.

Suggested INR Therapeutic Range for Vitamin K antagonist therapy:

LEVELS OF

THERAPY

Standard Dose

INDICATIONS

Venous Thrombosis,
Atrial Fibrillation,
Pulmonary Embolism.

TARGET INR RANGE

2.0 - 3.0

High Dose

Valvular Heart Disease,
Mechanical Heart,
Intracardiac Thrombosis.

2.5 - 3.5

PTT 25.9(*b) (23.9-32.8) Second

NOTES: (*b) Salt Lake Regional Lab
Salt Lake Regional Medical Center Laboratory, 1050 E S Temple
Salt Lake City, UT 84102
Richard Iverson, DO

RQ0010049799 - Miller, John R (SL30005675) DEP(/) 70/M Joanie Salotti, NP

Run Date: 06/24/23
Run Time: 0029

Phone: Medical Director:

PATIENT	SEX	AGE	DATE OF BIRTH	LOCATION	DATE PRINTED
Miller, John R	M	70	12/31/1952	SLCLAB	06/24/23
MED REC # / ACCT #	ADMIT DATE	DISCH DATE	SUBMITTING DOCTOR		
SL30005675 / RQ0010049799	06/20/23		Joanie Salotti, NP		

Chemistry

Date	06/20/2023		
Time	1225	Reference	Units
Na	137(*c)	(136-145)	mmol/L
K	3.9(*c)	(3.5-5.1)	mmol/L
CL	109(*c) H	(98-107)	mmol/L
CO2	24(*c)	(21-32)	mmol/L
Gap	7.9(*c)	(5.0-15.0)	mmol/L
BUN	28(*c) H	(7-18)	mg/dL
Creat	1.20(*c)	(0.70-1.30)	mg/dL
EGFR	65(E) L	(>=90 ml/mi	

(E) See (F), (*c)
(F) Reported eGFR is based on the CKD-EPI 2021 equation that does not use a race coefficient. Additional information can be found at:
02-10-8361_icb_egfr_summary_flyer5.pdf (kidney.org)

BUN/Creat Ratio	23.3(*c) H	(9.0-21.0)	ratio
Glu	104(G)	(65-109)	mg/dL

(G) See (H), (*c)
(H) Fasting Glucose Result Interpretation:
<100 mg/dL is within the Normal Range
100 - 125 mg/dL is Impaired
>126 mg/dL is a Provisional Diagnosis of Diabetes and must be confirmed by repeat testing on a different day

CA	9.2(*c)	(8.5-10.1)	mg/dL
Ferritin	66.1(*c)	(8.0-388.0)	ng/mL
Total Bili	0.6(*c)	(0.2-1.0)	mg/dL
GGT	44(*c)	(15-85)	U/L
AST	22(*c)	(15-37)	U/L
Alt	22(*c)	(16-61)	U/L

NOTES: (*c) Salt Lake Regional Lab
Salt Lake Regional Medical Center Laboratory, 1050 E S Temple
Salt Lake City, UT 84102
Richard Iverson, DO

RQ0010049799 - Miller, John R (SL30005675) DEP(/) 70/M Joanie Salotti, NP

Run Date: 06/24/23
Run Time: 0029

Phone:

Medical Director:

PATIENT	SEX	AGE	DATE OF BIRTH	LOCATION	DATE PRINTED
Miller, John R	M	70	12/31/1952	SLCLAB	06/24/23
MED REC # / ACCT #	ADMIT DATE	DISCH DATE	SUBMITTING DOCTOR		@ 0029
SL30005675 / RQ0010049799	06/20/23		Joanie Salotti, NP		

Chemistry (Cont.)

Date	06/20/2023		
Time	1225	Reference	Units
CRP	< 2.90(I)	(0.00-3.00)	mg/L

(I) See (J), (*d)

(J) CRP is a non-specific marker for inflammatory reactions and should not be used to diagnose specific disease.

Values above 10.0 mg/L may be indicative of inflammatory response but severity of disease cannot be determined by CRP levels. Serial measurement of CRP values may be useful in monitoring treatment but should not be used as the only indicator.

Patients with chronic high CRP levels may be at greater risk for stroke, myocardial infarction, and severe peripheral vascular disease.

When used as a risk marker, CRP results are used to assign risk as follows:

<1 mg/L Lowest risk
1-3 mg/L Average risk
>3 mg/L Highest risk

TP	7.0(*d)	(6.4-8.2)	g/dL
Alb	3.8(*d)	(3.4-5.0)	g/dL
Glob	3.2(*d)	(1.4-4.8)	g/dL
A/G Ratio	1.2(*d)	(1.0-10.0)	ratio
Trig	120(K)	(40-150)	mg/dL

(K) See (L), (*d)

(L) Triglycerides (mg/dL)

<150-Normal
150-199-Borderline High
200-499-High (Bad)
>500-Very High

NOTES: (*d) Salt Lake Regional Lab
Salt Lake Regional Medical Center Laboratory, 1050 E S Temple
Salt Lake City, UT 84102
Richard Iverson, DO

RQ0010049799 - Miller, John R (SL30005675) DEP(/) 70/M Joanie Salotti, NP

Run Date: 06/24/23
Run Time: 0029

Phone: Medical Director:

PATIENT	SEX	AGE	DATE OF BIRTH	LOCATION	DATE PRINTED
Miller, John R	M	70	12/31/1952	SICLAB	06/24/23
MED REC # / ACCT #	ADMIT DATE	DISCH DATE	SUBMITTING DOCTOR		
SL30005675 / RQ0010049799	06/20/23		Joanie Salotti, NP		

Chemistry (Cont.)

Date	06/20/2023		
Time	1225	Reference	Units
Chol	189(M)		mg/dL
(M)	See (N), (*e)		
(N)	Cholesterol, Total (mg/dL)		
	<200 Desirable		
	200-240 Borderline High		
	>240 High (Bad)		
Direct LDL	123(O)		mg/dL
(O)	See (P), (*e)		
(P)	LDL (mg/dL)		
	<100-Optimal		
	100-129-Near Optimal		
	130-159-Borderline High		
	160-189-High (Bad)		
VLDL	24(*e)	(5-40)	mg/dL
HDL	52(Q)		mg/dL
(Q)	See (R), (*e)		
(R)	HDL (mg/dL)		
	<40-Low		
	>59-High (Good)		
LDL/HDL Ratio	2(*e)		ratio
Chol/HDL Ratio	3.6(*e)	(0.0-5.0)	ratio
Alk Phos	94(*e)	(45-117)	U/L

NOTES: (*e) Salt Lake Regional Lab
Salt Lake Regional Medical Center Laboratory, 1050 E S Temple
Salt Lake City, UT 84102
Richard Iverson, DO

RQ0010049799 - Miller, John R (SL30005675) DEP(/) 70/M Joanie Salotti, NP

Run Date: 06/24/23
Run Time: 0029

Phone:

Medical Director:

PATIENT	SEX	AGE	DATE OF BIRTH	LOCATION	DATE PRINTED
Miller, John R	M	70	12/31/1952	SLCLAB	06/24/23
MED REC # / ACCT #	ADMIT DATE	DISCH DATE	SUBMITTING DOCTOR		@ 0029
SL30005675 / RQ0010049799	06/20/23		Joanie Salotti, NP		

Chemistry (Cont.)

Date 06/20/2023
Time 1225

Reference Units

PSA 18.800(S) H (0.000-4.00 ng/mL)

(S) See (T). (*f)

(T) Do not interpret serum PSA levels as absolute evidence of the presence or the absence of malignant disease. Before treatment, patients with confirmed prostatic carcinoma frequently have serum PSA levels within the range observed in healthy individuals. Additionally, elevated PSA levels can be observed in patients with nonmalignant diseases of the prostate. Use serum PSA levels in conjunction with information from the clinical evaluation of the patient and other diagnostic procedures. Patients results determined by assays using different manufactures for methods may not be comparable.

B12	518.00(*f)	(193.00-986 pg/mL
FSH	13.2(*g)	(1.4-18.1) mIU/mL
LH	3.52(*g)	
Prolactin	5.1(U)	ng/mL

(U) See (V). (*g)

(V) Reference Range:

Females non pregnant: 2.8 | 29.2 ng/mL
Females pregnant: 9.7 | 208.5 ng/mL
Females postmenopausal: 1.8 | 20.3 ng/mL
Males: 2.1 | 17.7 ng/mL

Test	Date	Time	Result	Reference	Units
Alb	06/20/2023	1225	3.9(*f)	(3.1-5.0)	g/dL

NOTES: (*f) Salt Lake Regional Lab
Salt Lake Regional Medical Center Laboratory, 1050 E S Temple
Salt Lake City, UT 84102
Richard Iverson, DO
(*g) Davis Hospital Med Laboratory
1600 West Antelope Drive, Layton, UT 84041
Scott Steiner, MD

RQ0010049799 - Miller, John R (SL30005675) DEP(/) 70/M Joanie Salotti, NP

Run Date: 06/24/23
Run Time: 0029

Phone:

Medical Director:

PATIENT	SEX	AGE	DATE OF BIRTH	LOCATION	DATE PRINTED
Miller, John R	M	70	12/31/1952	SLCLAB	06/24/23 @ 0029
MED REC # / ACCT #	ADMIT DATE	DISCH DATE	SUBMITTING DOCTOR		
SL30005675 / RQ0010049799	06/20/23		Joanie Salotti, NP		

Test	Date	Time	Result	Reference	Units
Testosterone	06/20/2023	1225	756.2(W)	(650.00-890.00)ng/dl	

(W) See (X), (*h)

(X) Testosterone, Age Normalized male:

40-59 years: 300.00-890.00 ng/dL

60years and over: 200.00-720.00 ng/dL

Age

7-9 month Tanner Stage I <30.00 ng/dL

10-13 years Tanner Stage II <150.00 ng/dL

14-15 years Tanner Stage III 100.00-320.00 ng/dL

16-19 years Tanner Stage IV 200.00-970.00 ng/dL

SHBG	06/20/2023	1225	41.11(*h)	(13.00-71.00)	nmol/L
Free Testo	06/20/2023	1225	15.89(*h)	(4.70-24.40)	ng/dL
% Free Test	06/20/2023	1225	2.10(*h)	(1.60-2.90)	%
Estradiol	06/20/2023	1225	30(Y)		pg/mL

(Y) See (Z), (*h)

(Z) "Ranges:

Male: 0.0-52.5 pg/mL

Female:

Postmenopausal (not on Hormone Therapy): 0.0-58.3 pg/mL

Non Pregnant Female:

Follicular Phase 21.4-164.8

Mid-Cycle Phase 49.9-367.2

Luteal Phase: 40.2-259.0

AFP	06/20/2023	1225	1.7(AA)	(0.0-8.4)	ng/mL
-----	------------	------	---------	-----------	-------

(AA) Roche Diagnostics Electrochemiluminescence Immunoassay (ECLIA)

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

This test is not interpretable in pregnant females.

NOTES: (*h) Salt Lake Regional Lab
Salt Lake Regional Medical Center Laboratory, 1050 E S Temple
Salt Lake City, UT 84102
Richard Iverson, DO

RQ0010049799 - Miller, John R (SL30005675) DEP(/) 70/M Joanie Salotti, NP

Run Date: 06/24/23
Run Time: 0029

Phone:

Medical Director:

PATIENT	SEX	AGE	DATE OF BIRTH	LOCATION	DATE PRINTED
Miller, John R	M	70	12/31/1952	SLCLAB	06/24/23
MED REC # / ACCT #	ADMIT DATE	DISCH DATE	SUBMITTING DOCTOR		
SL30005675 / RQ0010049799	06/20/23		Joanie Salotti, NP		

Test	Date	Time	Result	Reference	Units
AFP-L3%	06/20/2023	1225	(AB)	(0.0-9.9)	%

(AB) Comment

AFP-L3% result is below the detection limit of the assay.
Performed at: BN - Labcorp Burlington
1447 York Court, Burlington, NC 272153361
Lab Director: Sanjai Nagendra MD, Phone: 8007624344

RQ0010049799 - Miller, John R (SL30005675) DEP(/) 70/M Joanie Salotti, NP